Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16

Nadja Schoentgen; Julien Marolleau; Francky Delage; Jean-Baptiste Coquet; Alexandre Fourcade; Pierre Callerot; Sophie Serey-Eiffel; Jean-Pierre Malhaire; Olivier Pradier; Ulrike Schick; Georges Fournier; Antoine Valeri

doi:10.5114/jcb.2019.85793

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

3/2019
vol. 11

Send email

Copy url:

abstract:

Original paper

Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16

Nadja Schoentgen

¹

,

Julien Marolleau

^{1, 2, 3}

,

Francky Delage

¹

,

Jean-Baptiste Coquet

¹

,

Alexandre Fourcade

^{1, 2, 3}

,

Pierre Callerot

¹

,

Sophie Serey-Eiffel

¹

,

Jean-Pierre Malhaire

⁴

,

Olivier Pradier

^{2, 3, 4, 5}

,

Ulrike Schick

^{2, 3, 4, 5}

,

Georges Fournier

^{1, 2, 3, 5, 6}

,

Antoine Valeri

^{1, 2, 3, 5, 6}

CHU Brest, Service Urologie, Brest, France,
Université de Brest, Faculté de Médecine et des Sciences de la Santé, Brest, France
Université Bretagne Loire, Rennes, France
CHU Brest, Service de Radiothérapie, Brest, France
LaTIM, INSERM, UMR 1101, Univ Brest, Brest, France
CeRePP, Paris, France

J Contemp Brachytherapy 2019; 11, 3: 195–200

DOI: https://doi.org/10.5114/jcb.2019.85793

Online publish date: 2019/06/18

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Schoentgen N, Marolleau J, Delage F, et al. Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. Journal of Contemporary Brachytherapy. 2019;11(3):195-200. doi:10.5114/jcb.2019.85793.

APA

Schoentgen, N., Marolleau, J., Delage, F., Coquet, J., Fourcade, A.,  & Callerot, P. et al. (2019). Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. Journal of Contemporary Brachytherapy, 11(3), 195-200. https://doi.org/10.5114/jcb.2019.85793

Chicago

Schoentgen, Nadja, Julien Marolleau, Francky Delage, Jean-Baptiste Coquet, Alexandre Fourcade, Pierre Callerot,  and Sophie Serey-Eiffel et al. 2019. "Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16". Journal of Contemporary Brachytherapy 11 (3): 195-200. doi:10.5114/jcb.2019.85793.

Harvard

Schoentgen, N., Marolleau, J., Delage, F., Coquet, J., Fourcade, A., Callerot, P., Serey-Eiffel, S., Malhaire, J., Pradier, O., Schick, U., Fournier, G.,  and Valeri, A. (2019). Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. Journal of Contemporary Brachytherapy, 11(3), pp.195-200. https://doi.org/10.5114/jcb.2019.85793

MLA

Schoentgen, Nadja et al. "Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16." Journal of Contemporary Brachytherapy, vol. 11, no. 3, 2019, pp. 195-200. doi:10.5114/jcb.2019.85793.

Vancouver

Schoentgen N, Marolleau J, Delage F, Coquet J, Fourcade A, Callerot P et al. Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16. Journal of Contemporary Brachytherapy. 2019;11(3):195-200. doi:10.5114/jcb.2019.85793.

Purpose
Prostate brachytherapy (BT) is a validated treatment for localized prostate cancer (CaP) and an attractive therapy option for patients seeking to preserve erectile function (EF). The aim of this paper is to prospectively assess EF evolution during 4 years after BT.

Material and methods
Between February 2007 and July 2012, 179 patients underwent an exclusive Iodine-125 BT, for low-intermediate favorable risk CaP of whom, 102 had an initial international index of erectile function 5 score (IIEF-5) > 16 and were included in the study. Of those, 12.7% received neo-adjuvant hormonotherapy (HT) to decrease the prostate volume. Post-BT intake of phosphodiesterase inhibitors (PDE5i) was not an exclusion criterion. Erectile function was prospectively assessed using a validated questionnaire IIEF-5 before treatment and annually for 4 years.

Results
At 1-year follow-up, 54% of patients preserved an IIEF-5 > 16 and only 8% suffered from severe ED. During the next 3 years, the results were not statistically different. The mean IIEF-5 lost 4 points during the first year, 17 vs. 21, and remained stable during the following 3 years. We did not find any significant differences in the proportion of patients treated by PDE5i (18-20%). As for patients with a normal preoperative IIEF-5 (> 21) (n = 52), 35-42% preserved a normal EF and 71-77% maintained an IIEF-5 > 16, including 13-19% of patients who needed PDE5i. Those results were stable for over 4 years.

Conclusions
During the first 4 years after BT, more than half of patients maintained an IIEF-5 > 16, and EF results remained stable. Severe erectile dysfunction (ED) was very rare.

keywords:

Prospective four years of evaluation of erectile function after low-dose-rate prostate brachytherapy using baseline IIEF-5 > 16

prostate cancer, erectile dysfunction, brachytherapy, radiation therapy, IIEF-5